CSF2RA and KIT |
colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) |
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog |
- Signaling by GPCR
- G-protein beta:gamma signalling
- Cytokine Signaling in Immune system
- GPCR downstream signaling
- Signaling by Interleukins
- Interleukin receptor SHC signaling
- G beta:gamma signalling through PI3Kgamma
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Regulation of KIT signaling
- PI3K/AKT activation
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- Signalling by NGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by ERBB4
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
|
- Sorafenib
- Imatinib
- Dasatinib
- Sunitinib
- Phosphonotyrosine
- Adenosine-5\'-Diphosphate
- Nilotinib
- Pazopanib
- Regorafenib
- Ponatinib
|
|
|
CSF2RA and PIK3R1 |
colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
- Signaling by GPCR
- G-protein beta:gamma signalling
- Cytokine Signaling in Immune system
- GPCR downstream signaling
- Signaling by Interleukins
- Interleukin receptor SHC signaling
- G beta:gamma signalling through PI3Kgamma
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Interleukin-7 signaling
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by Interleukins
- TCR signaling
- Signaling by VEGF
- GP1b-IX-V activation signalling
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
|
- Isoproterenol
- (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
|
|
|
CSF2RA and RPSA |
colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) |
ribosomal protein SA |
- Signaling by GPCR
- G-protein beta:gamma signalling
- Cytokine Signaling in Immune system
- GPCR downstream signaling
- Signaling by Interleukins
- Interleukin receptor SHC signaling
- G beta:gamma signalling through PI3Kgamma
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
|
- Nonsense-Mediated Decay (NMD)
- Translation initiation complex formation
- Translation
- SRP-dependent cotranslational protein targeting to membrane
- Eukaryotic Translation Termination
- Peptide chain elongation
- Influenza Infection
- Viral mRNA Translation
- L13a-mediated translational silencing of Ceruloplasmin expression
- Influenza Life Cycle
- Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
- Ribosomal scanning and start codon recognition
- Formation of the ternary complex, and subsequently, the 43S complex
- Influenza Viral RNA Transcription and Replication
- GTP hydrolysis and joining of the 60S ribosomal subunit
- Eukaryotic Translation Initiation
- Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
- Formation of a pool of free 40S subunits
- Eukaryotic Translation Elongation
- Cap-dependent Translation Initiation
- Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
|
|
|
|
|
CSF2RA and CSF2RB |
colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) |
colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) |
- Signaling by GPCR
- G-protein beta:gamma signalling
- Cytokine Signaling in Immune system
- GPCR downstream signaling
- Signaling by Interleukins
- Interleukin receptor SHC signaling
- G beta:gamma signalling through PI3Kgamma
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
|
- Signaling by GPCR
- G-protein beta:gamma signalling
- Cytokine Signaling in Immune system
- GPCR downstream signaling
- Signaling by Interleukins
- Interleukin receptor SHC signaling
- G beta:gamma signalling through PI3Kgamma
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
|
|
|
|
|
CSF2RA and FATE1 |
colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) |
fetal and adult testis expressed 1 |
- Signaling by GPCR
- G-protein beta:gamma signalling
- Cytokine Signaling in Immune system
- GPCR downstream signaling
- Signaling by Interleukins
- Interleukin receptor SHC signaling
- G beta:gamma signalling through PI3Kgamma
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
|
|
|
|
|
|
CSF2RA and IKBKB |
colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta |
- Signaling by GPCR
- G-protein beta:gamma signalling
- Cytokine Signaling in Immune system
- GPCR downstream signaling
- Signaling by Interleukins
- Interleukin receptor SHC signaling
- G beta:gamma signalling through PI3Kgamma
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
|
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- RIP-mediated NFkB activation via ZBP1
- IRAK1 recruits IKK complex
- Downstream signaling events of B Cell Receptor (BCR)
- Toll Like Receptor TLR1:TLR2 Cascade
- FCERI mediated NF-kB activation
- Toll Like Receptor 5 (TLR5) Cascade
- NOD1/2 Signaling Pathway
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- IRAK1 recruits IKK complex
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- TCR signaling
- Signaling by Interleukins
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Fc epsilon receptor (FCERI) signaling
- Interleukin-1 signaling
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Downstream TCR signaling
- p75NTR recruits signalling complexes
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Innate Immune System
- Signalling by NGF
- IKK complex recruitment mediated by RIP1
- Cytosolic sensors of pathogen-associated DNA
- p75 NTR receptor-mediated signalling
- Cytokine Signaling in Immune system
- MyD88-independent cascade
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Activation of NF-kappaB in B cells
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
|
- Mesalazine
- Sulfasalazine
- Auranofin
- Arsenic trioxide
|
|
|
CSF2RB and IL3RA |
colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) |
interleukin 3 receptor, alpha (low affinity) |
- Signaling by GPCR
- G-protein beta:gamma signalling
- Cytokine Signaling in Immune system
- GPCR downstream signaling
- Signaling by Interleukins
- Interleukin receptor SHC signaling
- G beta:gamma signalling through PI3Kgamma
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
|
- Signaling by GPCR
- G-protein beta:gamma signalling
- Cytokine Signaling in Immune system
- GPCR downstream signaling
- Signaling by Interleukins
- Interleukin receptor SHC signaling
- G beta:gamma signalling through PI3Kgamma
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
|
|
|
|
|
CSNK2A1 and GABRR1 |
casein kinase 2, alpha 1 polypeptide |
gamma-aminobutyric acid (GABA) A receptor, rho 1 |
- Mitotic Prometaphase
- Signal transduction by L1
- Axon guidance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- L1CAM interactions
- Signaling by Wnt
- Cell Cycle, Mitotic
- M Phase
- WNT mediated activation of DVL
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by WNT in cancer
- Condensation of Prometaphase Chromosomes
|
- GABA receptor activation
- GABA A (rho) receptor activation
- Ion channel transport
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ligand-gated ion channel transport
- Transmission across Chemical Synapses
|
- (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
- 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
- Resveratrol
- 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
- Benzamidine
- 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
- Phosphoaminophosphonic Acid-Adenylate Ester
- Tetrabromo-2-Benzotriazole
- DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
- S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
- 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
- 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
- N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
- 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
- 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
- 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
- 1,2,5,8-tetrahydroxyanthracene-9,10-dione
- Ellagic Acid
|
- Lorazepam
- Temazepam
- Clobazam
- Alprazolam
- Picrotoxin
- Chlordiazepoxide
- Adinazolam
- Clorazepate
- Midazolam
- Flurazepam
- Halazepam
- Diazepam
- Oxazepam
- Triazolam
- Clonazepam
- Estazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
|
|
|
CSNK2A1 and CTDP1 |
casein kinase 2, alpha 1 polypeptide |
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 |
- Mitotic Prometaphase
- Signal transduction by L1
- Axon guidance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- L1CAM interactions
- Signaling by Wnt
- Cell Cycle, Mitotic
- M Phase
- WNT mediated activation of DVL
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by WNT in cancer
- Condensation of Prometaphase Chromosomes
|
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- RNA Polymerase II Transcription
- Abortive elongation of HIV-1 transcript in the absence of Tat
- HIV Infection
- Formation of the Early Elongation Complex
- Tat-mediated elongation of the HIV-1 transcript
- Tat-mediated HIV elongation arrest and recovery
- RNA Polymerase II Pre-transcription Events
- Late Phase of HIV Life Cycle
- Pausing and recovery of Tat-mediated HIV elongation
- Formation of RNA Pol II elongation complex
- HIV elongation arrest and recovery
- HIV Life Cycle
- Pausing and recovery of HIV elongation
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- HIV Transcription Elongation
- Transcription of the HIV genome
- RNA Polymerase II Transcription Elongation
|
- (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
- 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
- Resveratrol
- 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
- Benzamidine
- 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
- Phosphoaminophosphonic Acid-Adenylate Ester
- Tetrabromo-2-Benzotriazole
- DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
- S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
- 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
- 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
- N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
- 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
- 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
- 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
- 1,2,5,8-tetrahydroxyanthracene-9,10-dione
- Ellagic Acid
|
|
|
|
CSNK2A1 and KIF5C |
casein kinase 2, alpha 1 polypeptide |
kinesin family member 5C |
- Mitotic Prometaphase
- Signal transduction by L1
- Axon guidance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- L1CAM interactions
- Signaling by Wnt
- Cell Cycle, Mitotic
- M Phase
- WNT mediated activation of DVL
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by WNT in cancer
- Condensation of Prometaphase Chromosomes
|
- Peptide hormone metabolism
- Insulin processing
|
- (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
- 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
- Resveratrol
- 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
- Benzamidine
- 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
- Phosphoaminophosphonic Acid-Adenylate Ester
- Tetrabromo-2-Benzotriazole
- DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
- S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
- 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
- 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
- N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
- 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
- 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
- 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
- 1,2,5,8-tetrahydroxyanthracene-9,10-dione
- Ellagic Acid
|
|
|
|
CSNK2A1 and FXR1 |
casein kinase 2, alpha 1 polypeptide |
fragile X mental retardation, autosomal homolog 1 |
- Mitotic Prometaphase
- Signal transduction by L1
- Axon guidance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- L1CAM interactions
- Signaling by Wnt
- Cell Cycle, Mitotic
- M Phase
- WNT mediated activation of DVL
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by WNT in cancer
- Condensation of Prometaphase Chromosomes
|
|
- (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
- 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
- Resveratrol
- 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
- Benzamidine
- 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
- Phosphoaminophosphonic Acid-Adenylate Ester
- Tetrabromo-2-Benzotriazole
- DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
- S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
- 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
- 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
- N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
- 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
- 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
- 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
- 1,2,5,8-tetrahydroxyanthracene-9,10-dione
- Ellagic Acid
|
|
|
|
CSNK2A2 and CTDP1 |
casein kinase 2, alpha prime polypeptide |
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 |
- Mitotic Prometaphase
- Signal transduction by L1
- Axon guidance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- L1CAM interactions
- Signaling by Wnt
- Cell Cycle, Mitotic
- M Phase
- WNT mediated activation of DVL
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by WNT in cancer
- Condensation of Prometaphase Chromosomes
|
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- RNA Polymerase II Transcription
- Abortive elongation of HIV-1 transcript in the absence of Tat
- HIV Infection
- Formation of the Early Elongation Complex
- Tat-mediated elongation of the HIV-1 transcript
- Tat-mediated HIV elongation arrest and recovery
- RNA Polymerase II Pre-transcription Events
- Late Phase of HIV Life Cycle
- Pausing and recovery of Tat-mediated HIV elongation
- Formation of RNA Pol II elongation complex
- HIV elongation arrest and recovery
- HIV Life Cycle
- Pausing and recovery of HIV elongation
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- HIV Transcription Elongation
- Transcription of the HIV genome
- RNA Polymerase II Transcription Elongation
|
|
|
|
|
CSNK2B and CTDP1 |
casein kinase 2, beta polypeptide |
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 |
- Mitotic Prometaphase
- Signal transduction by L1
- Axon guidance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- L1CAM interactions
- Signaling by Wnt
- Cell Cycle, Mitotic
- M Phase
- WNT mediated activation of DVL
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by WNT in cancer
- Condensation of Prometaphase Chromosomes
|
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- RNA Polymerase II Transcription
- Abortive elongation of HIV-1 transcript in the absence of Tat
- HIV Infection
- Formation of the Early Elongation Complex
- Tat-mediated elongation of the HIV-1 transcript
- Tat-mediated HIV elongation arrest and recovery
- RNA Polymerase II Pre-transcription Events
- Late Phase of HIV Life Cycle
- Pausing and recovery of Tat-mediated HIV elongation
- Formation of RNA Pol II elongation complex
- HIV elongation arrest and recovery
- HIV Life Cycle
- Pausing and recovery of HIV elongation
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- HIV Transcription Elongation
- Transcription of the HIV genome
- RNA Polymerase II Transcription Elongation
|
|
|
|
|
CSNK2B and BAG6 |
casein kinase 2, beta polypeptide |
BCL2-associated athanogene 6 |
- Mitotic Prometaphase
- Signal transduction by L1
- Axon guidance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- L1CAM interactions
- Signaling by Wnt
- Cell Cycle, Mitotic
- M Phase
- WNT mediated activation of DVL
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by WNT in cancer
- Condensation of Prometaphase Chromosomes
|
|
|
|
|
|
VCAN and CXCL12 |
versican |
chemokine (C-X-C motif) ligand 12 |
- MPS IIIB - Sanfilippo syndrome B
- Diseases of glycosylation
- Heparan sulfate/heparin (HS-GAG) metabolism
- Defective B4GALT7 causes EDS, progeroid type
- MPS I - Hurler syndrome
- MPS IX - Natowicz syndrome
- Chondroitin sulfate/dermatan sulfate metabolism
- CS/DS degradation
- Defective SLC26A2 causes chondrodysplasias
- Glycosaminoglycan metabolism
- Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
- Defective CHST14 causes EDS, musculocontractural type
- Defective PAPSS2 causes SEMD-PA
- MPS IIIA - Sanfilippo syndrome A
- Myoclonic epilepsy of Lafora
- ECM proteoglycans
- Defective CHST6 causes MCDC1
- Glycogen storage diseases
- MPS IIID - Sanfilippo syndrome D
- A tetrasaccharide linker sequence is required for GAG synthesis
- Chondroitin sulfate biosynthesis
- MPS IIIC - Sanfilippo syndrome C
- Diseases associated with glycosaminoglycan metabolism
- Mucopolysaccharidoses
- Defective EXT2 causes exostoses 2
- MPS II - Hunter syndrome
- Defective B3GAT3 causes JDSSDHD
- Defective CHST3 causes SEDCJD
- Defective EXT1 causes exostoses 1, TRPS2 and CHDS
- MPS IV - Morquio syndrome A
- Dermatan sulfate biosynthesis
- Defective CHSY1 causes TPBS
- MPS IV - Morquio syndrome B
- MPS VII - Sly syndrome
- Metabolism of carbohydrates
- MPS VI - Maroteaux-Lamy syndrome
|
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- Signaling by GPCR
- Class A/1 (Rhodopsin-like receptors)
- Signaling by ERBB4
- GPCR ligand binding
- Metabolic disorders of biological oxidation enzymes
- GPCR downstream signaling
- Nuclear signaling by ERBB4
- Peptide ligand-binding receptors
- Chemokine receptors bind chemokines
- G alpha (i) signalling events
|
|
|
|
|
CSTF2 and BAG6 |
cleavage stimulation factor, 3 pre-RNA, subunit 2, 64kDa |
BCL2-associated athanogene 6 |
- mRNA Splicing
- Processing of Capped Intron-Containing Pre-mRNA
- RNA Polymerase II Transcription
- Processing of Capped Intronless Pre-mRNA
- mRNA Splicing - Major Pathway
- Cleavage of Growing Transcript in the Termination Region
- RNA Polymerase II Transcription Termination
- mRNA 3'-end processing
- Processing of Intronless Pre-mRNAs
|
|
|
|
|
|
CSTF2 and FEZ1 |
cleavage stimulation factor, 3 pre-RNA, subunit 2, 64kDa |
fasciculation and elongation protein zeta 1 (zygin I) |
- mRNA Splicing
- Processing of Capped Intron-Containing Pre-mRNA
- RNA Polymerase II Transcription
- Processing of Capped Intronless Pre-mRNA
- mRNA Splicing - Major Pathway
- Cleavage of Growing Transcript in the Termination Region
- RNA Polymerase II Transcription Termination
- mRNA 3'-end processing
- Processing of Intronless Pre-mRNAs
|
|
|
|
|
|
CTAG1B and HLA-DRB1 |
cancer/testis antigen 1B |
major histocompatibility complex, class II, DR beta 1 |
|
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
|
|
|
|
CTBP1 and HDAC4 |
C-terminal binding protein 1 |
histone deacetylase 4 |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- Degradation of beta-catenin by the destruction complex
- S37 mutants of beta-catenin aren't phosphorylated
- S33 mutants of beta-catenin aren't phosphorylated
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- XAV939 inhibits tankyrase, stabilizing AXIN
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- deletions in the AMER1 gene destabilize the destruction complex
- TCF dependent signaling in response to WNT
- AMER1 mutants destabilize the destruction complex
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
|
|
|
|
|
CTBP1 and TCF4 |
C-terminal binding protein 1 |
transcription factor 4 |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- Degradation of beta-catenin by the destruction complex
- S37 mutants of beta-catenin aren't phosphorylated
- S33 mutants of beta-catenin aren't phosphorylated
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- XAV939 inhibits tankyrase, stabilizing AXIN
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- deletions in the AMER1 gene destabilize the destruction complex
- TCF dependent signaling in response to WNT
- AMER1 mutants destabilize the destruction complex
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
- CDO in myogenesis
- Myogenesis
|
|
|
|
|